This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with ...
Zacks Investment Research on MSN7h
FDA Approves Novartis Drug for Rare Kidney Disease TreatmentNovartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved ...
The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.
The FDA on Thursday approved Fabhalta (iptacopan) to treat complement 3 glomerulopathy (CG3), a progressive, ultrarare kidney ...
Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...
Fosamax further defines the obligation of drug manufacturers to present clear, unambiguous, and accurate information to the ...
Dermatologists are increasingly prescribing minoxidil in low-dose pills to help men and women regrow hair. The practice ...
MedPage Today on MSN21h
First Drug Approved for Ultra-Rare Kidney DiseaseThe FDA approved iptacopan (Fabhalta) as the first treatment to reduce proteinuria in adults with complement 3 glomerulopathy ...
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA ...
Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.
FDA accepts Capricor's Biologics License Application for priority review, advancing deramiocel for DMD cardiomyopathy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback